Recombinant Mouse P2Y purinoceptor 12 (P2ry12)

What is P2Y purinoceptor 12 and what are its primary functions?

P2Y purinoceptor 12 (P2ry12) is a G protein-coupled purinergic nucleotide receptor that plays crucial roles in several physiological processes. In platelets, it mediates ADP-induced platelet activation and is essential for normal hemostasis . P2ry12 is also expressed in microglia where it regulates microglial cell activation. In zebrafish models, it has been shown to be involved in the regulation of primitive erythrocyte differentiation . The receptor is predominantly located in the plasma membrane and functions through inhibition of adenylyl cyclase, leading to decreased cAMP levels .

What is the protein structure of mouse P2ry12 and how does it compare to human P2RY12?

Mouse P2ry12 is a rhodopsin-like 7-transmembrane G protein-coupled receptor. According to the zebrafish database, the protein length is approximately 345 amino acids . The mouse P2ry12 shares significant structural homology with human P2RY12, particularly in the transmembrane domains and ligand-binding sites. Both contain a PDZ-binding motif at the C-terminus that is critical for receptor trafficking and function as demonstrated in human studies . This structural conservation suggests similar trafficking mechanisms and functional properties between species, making mouse models valuable for studying P2ry12-related pathologies relevant to humans.

How is P2ry12 expression regulated in different tissues?

P2ry12 expression shows tissue-specific patterns. In zebrafish, it is expressed in the axial blood vessel, head, and hematopoietic system . In mammals, including mice, P2ry12 is predominantly expressed in platelets where it mediates ADP-induced platelet aggregation. It is also significantly expressed in microglia in the central nervous system, where it serves as a reliable marker for homeostatic microglia . Expression levels can be modulated by various inflammatory stimuli and pathological conditions, with microglial P2ry12 typically downregulated during activation in response to injury or inflammation. The receptor's expression is regulated at both transcriptional and post-transcriptional levels, with evidence for specific regulatory elements in its promoter region controlling tissue-specific expression.

What are the most effective antibodies for mouse P2ry12 detection in different applications?

Multiple validated antibodies are available for mouse P2ry12 detection across various experimental applications. For flow cytometry and immunohistochemistry on paraffin-embedded tissues (IHC-p), BioLegend offers purified anti-mouse P2ry12 antibodies that have been cited in numerous publications (36 citations for their 100 μg product) . For Western blotting applications, antibodies from Novus Biologicals and BosterBio have demonstrated reliable detection of mouse P2ry12 .

For researchers requiring more specialized applications, a comparison of commonly used P2ry12 antibodies is provided below:

When selecting antibodies, researchers should prioritize those with validation data specific to their experimental system and application.

What are the best methods for studying P2ry12 trafficking in cell models?

Based on the research on human P2RY12, studying P2ry12 trafficking requires techniques that can visualize receptor internalization and recycling. Recommended methods include:

• N-terminal epitope tagging of P2ry12 (such as HA-tagging) followed by ELISA or immunofluorescence microscopy to quantify surface receptor loss and recycling after agonist exposure .

• Co-expression of fluorescently tagged arrestins (arrestin-2-GFP or arrestin-3-GFP) with P2ry12 to visualize arrestin translocation upon receptor activation, a key step in receptor internalization .

• Coimmunoprecipitation experiments to investigate protein-protein interactions, particularly between P2ry12 and trafficking regulatory proteins such as arrestins .

• Mutagenesis of key receptor domains, especially the C-terminal PDZ-binding motif (ETPM in human), followed by functional assays to determine the impact on receptor trafficking .

These methods can be adapted to mouse P2ry12 studies, with consideration for species-specific differences in the receptor sequence and interacting proteins.

How can I effectively measure P2ry12-mediated signaling in vitro?

P2ry12 primarily couples to Gi proteins, inhibiting adenylyl cyclase and reducing intracellular cAMP levels. Therefore, effective measurement of P2ry12 signaling can be achieved through:

• cAMP assays: Measure inhibition of forskolin-stimulated adenylyl cyclase activity. This can be accomplished using commercially available cAMP ELISA kits or FRET-based sensors .

• GTPγS binding assays: Quantify G-protein activation by measuring the binding of non-hydrolyzable GTP analogs to G proteins upon receptor stimulation.

• Calcium mobilization assays: Although P2ry12 does not directly couple to calcium signaling, secondary calcium responses can be measured using calcium-sensitive dyes.

• Arrestin recruitment assays: BRET or FRET-based assays to measure the kinetics of arrestin recruitment to the activated receptor .

• Receptor internalization assays: Quantify surface receptor loss following agonist stimulation using antibodies against N-terminal tags or against the receptor itself .

When designing these experiments, it's critical to include appropriate controls, such as P2ry12 antagonists (e.g., AR-C69931MX) and cells lacking P2ry12 expression, to confirm signal specificity.

How does P2ry12 function differ in activated versus resting microglia?

P2ry12 serves as a key marker for homeostatic (resting) microglia and undergoes significant changes during microglial activation. In resting microglia, P2ry12 is abundantly expressed and mediates process extension toward sites of injury or ATP release, facilitating the microglial surveillance function. Upon activation, particularly in neurodegenerative conditions, P2ry12 expression is typically downregulated .

This differential expression pattern makes P2ry12 a valuable marker for distinguishing microglial activation states in research and diagnostic applications. In pathologically-involved brains, P2ry12 expression can identify microglia with various morphologies associated with different activation states . This dynamic regulation suggests that P2ry12 signaling may play different roles depending on the microglial activation state, with implications for neuroinflammatory and neurodegenerative disease research.

What phenotypes are observed in P2ry12 knockout mouse models?

P2ry12 knockout mice exhibit several distinct phenotypes reflecting the receptor's physiological roles:

• Platelet function: P2ry12-deficient mice show significantly prolonged bleeding times and reduced platelet aggregation in response to ADP, similar to the platelet-type bleeding disorder 8 observed in humans with P2RY12 mutations .

• Microglial responses: Knockout mice demonstrate impaired microglial chemotaxis toward sites of injury or ATP release in the brain, with reduced process extension and delayed response to focal brain injury.

• Vascular development: Based on zebrafish studies, P2ry12 is involved in the regulation of primitive erythrocyte differentiation, suggesting potential roles in hematopoietic development .

• Neuroinflammatory responses: P2ry12-deficient mice show altered microglial responses in models of multiple sclerosis, stroke, and other neuroinflammatory conditions, typically with reduced microglial accumulation at lesion sites.

These phenotypes underscore the multiple physiological roles of P2ry12 and provide valuable models for studying its function in different pathological contexts.

How is P2ry12 implicated in human diseases and what are the corresponding mouse models?

P2ry12 orthologues in humans are implicated in several pathological conditions that can be modeled in mice:

These disease associations highlight the potential of P2ry12 as a therapeutic target across multiple conditions, with mouse models providing valuable platforms for preclinical studies.

How does the C-terminal PDZ-binding motif regulate P2ry12 trafficking and function?

The C-terminal PDZ-binding motif of P2ry12 plays a critical role in receptor trafficking and function. Studies on human P2RY12 have revealed that the extreme C-terminal sequence (ETPM) constitutes a PDZ-binding motif essential for normal receptor internalization and recycling .

Deletion or mutation of this motif (such as the P341A mutation identified in a human subject) leads to:

• Attenuated receptor internalization following agonist stimulation

• Blocked receptor recycling to the cell surface

• Retention of receptors in intracellular sorting compartments

• Impaired interaction with arrestins, which are critical for receptor internalization

These trafficking defects prevent receptor resensitization, a process essential for normal P2ry12 function. The physiological significance of this regulatory mechanism is underscored by the identification of a human subject with a P341A mutation in the PDZ-binding motif who exhibited compromised P2ry12 trafficking in platelets .

This mechanism likely extends to mouse P2ry12, suggesting that the PDZ-binding motif represents a critical regulatory element for purinergic receptor function across species and a potential target for therapeutic interventions.

What is known about the interactions between P2ry12 and arrestins in receptor trafficking?

P2ry12 internalization is arrestin-dependent, with receptor activation leading to rapid recruitment of arrestin-2 and arrestin-3 from the cytosol to the membrane in transfected cell lines . Research has revealed several key aspects of this interaction:

• Arrestin recruitment: Activation of P2ry12 with agonists such as ADP leads to rapid translocation of arrestin-2-GFP and arrestin-3-GFP from the cytosol to the membrane .

• Dependence on PDZ-binding motif: Deletion or mutation of the PDZ-binding motif (ETPM) at the C-terminus of P2ry12 prevents arrestin recruitment upon receptor activation .

• Coimmunoprecipitation: Arrestin-2 can be coprecipitated with wild-type P2ry12 after agonist addition but not with mutants lacking the PDZ-binding motif (T320stop, E339stop, or P341A) .

• Functional impact of arrestin: Overexpression of a dominant-negative arrestin mutant (arrestin-DNM) selectively attenuates agonist-induced internalization of wild-type P2ry12 but not mutant receptors .

These findings suggest that the PDZ-binding motif of P2ry12 is required for arrestin binding and subsequent arrestin-dependent receptor internalization. The exact molecular mechanism by which the PDZ-binding motif facilitates arrestin recruitment remains to be fully elucidated and represents an important area for future research.

How does recombinant P2ry12 expression level influence experimental outcomes in heterologous systems?

The expression level of recombinant P2ry12 in heterologous systems can significantly impact experimental outcomes and must be carefully controlled:

• Receptor density effects: High expression levels can lead to constitutive activity or altered trafficking dynamics that don't reflect physiological conditions. Studies should include quantification of surface receptor density using ligand binding assays, as demonstrated with [³H]-2MeSADP for P2ry12 receptor constructs .

• G protein coupling efficiency: Overexpression may saturate the available G proteins or other signaling components, potentially masking subtle differences between wild-type and mutant receptors. This is particularly relevant when measuring inhibition of forskolin-stimulated adenylyl cyclase .

• Arrestin recruitment: The relative expression levels of receptors and arrestins can influence the kinetics and extent of arrestin recruitment. Standardized expression levels are essential for comparative studies of arrestin-dependent internalization .

• Trafficking dynamics: Expression levels can affect the rate and extent of receptor internalization and recycling. Stable expression systems with controlled receptor levels are preferable for trafficking studies .

To mitigate these issues, researchers should:

• Establish stable cell lines with comparable expression levels between wild-type and mutant receptors

• Quantify surface receptor expression using binding assays or flow cytometry

• Include appropriate positive and negative controls in all experiments

• Consider using inducible expression systems to regulate receptor levels precisely

What are common pitfalls in generating functional recombinant mouse P2ry12?

Generating functional recombinant mouse P2ry12 presents several challenges that researchers should anticipate:

• C-terminal modifications: The C-terminus of P2ry12 contains a critical PDZ-binding motif (ETPM) essential for normal trafficking and function. Adding tags to this region may disrupt receptor function. Research has shown that complete deletion of the C-tail (K303stop in human P2RY12) prevents surface expression . N-terminal tagging (e.g., HA-tag) is preferable for maintaining receptor functionality.

• Expression level optimization: Both over- and under-expression can lead to misleading results. Excessively high expression may cause receptor aggregation or constitutive activity, while insufficient expression may yield signals too weak for reliable detection.

• Post-translational modifications: P2ry12 undergoes various post-translational modifications that may differ between expression systems. Mammalian cell lines (e.g., CHO cells) are generally preferable to maintain proper glycosylation and other modifications .

• Species-specific differences: While mouse and human P2ry12 share significant homology, subtle differences exist that may affect ligand binding, signaling, or protein-protein interactions. Species-matched experimental systems should be used whenever possible.

• Receptor instability: Some mutations or truncations may create unstable proteins prone to degradation, as observed with certain human P2RY12 variants . Protein stabilization approaches (e.g., lower incubation temperatures, proteasome inhibitors) may help in studying these variants.

How can I optimize detection of low-level P2ry12 expression in non-canonical tissues?

Detecting low-level P2ry12 expression in tissues other than platelets and microglia requires optimized approaches:

• Antibody selection: Choose high-affinity antibodies with validation data in the specific tissue of interest. Consider antibodies from BioLegend or Novus Biologicals that have been validated for multiple applications .

• Signal amplification techniques:

  • For immunohistochemistry: Implement tyramide signal amplification (TSA) or polymer-based detection systems

  • For Western blotting: Use high-sensitivity ECL substrates and longer exposure times

  • For RT-PCR: Employ nested PCR approaches or digital PCR for absolute quantification of low-abundance transcripts

• Tissue preparation optimization:

  • For fixed tissues: Test multiple fixation methods as overfixation can mask epitopes

  • For frozen tissues: Optimize section thickness (8-10 μm typically provides good signal-to-noise ratio)

  • For protein extraction: Use specialized extraction buffers optimized for membrane proteins

• Positive and negative controls:

  • Include tissues known to express high levels of P2ry12 (e.g., spleen for platelets, brain for microglia)

  • Use P2ry12 knockout tissues or cells treated with P2ry12-specific siRNA as negative controls

  • Consider using recombinant P2ry12 protein as a positive control for antibody validation

• Single-cell approaches:

  • Single-cell RNA-seq can detect P2ry12 expression in rare cell populations

  • Flow cytometry with high-sensitivity detection systems can identify cells with low surface expression

What are the best approaches to distinguish between different P2Y receptor subtypes in functional assays?

Distinguishing between P2ry12 and other P2Y receptor subtypes in functional assays is challenging due to overlapping ligand specificities and expression patterns. Recommended approaches include:

• Pharmacological discrimination:

  • Use subtype-selective antagonists: AR-C69931MX (cangrelor) for P2ry12, MRS2500 for P2Y1

  • Employ selective agonists: 2MeSADP shows higher potency at P2ry12 than at P2Y1

  • Create concentration-response curves with multiple ligands to develop a pharmacological fingerprint

• Genetic approaches:

  • Use cells from P2ry12 knockout mice as negative controls

  • Implement CRISPR-Cas9 gene editing to create receptor-specific knockouts in cell lines

  • Utilize siRNA-mediated knockdown with validation of subtype-specific suppression

• Signaling pathway discrimination:

  • P2ry12 couples primarily to Gi, inhibiting cAMP production

  • P2Y1 couples to Gq, stimulating PLC and calcium mobilization

  • Monitor multiple signaling pathways simultaneously to create a signaling signature

• Receptor trafficking patterns:

  • Different P2Y subtypes show distinct internalization and recycling kinetics

  • P2ry12 requires an intact PDZ-binding motif for normal trafficking

  • Study receptor trafficking using subtype-specific antibodies or epitope-tagged receptors

• Expression pattern analysis:

  • Combine functional assays with expression profiling in the same samples

  • Use single-cell approaches to correlate receptor expression with functional responses

A combination of these approaches provides the most reliable discrimination between P2Y receptor subtypes and minimizes misinterpretation of experimental results.

How is P2ry12 involved in microglia-neuron communication in neurodegenerative conditions?

P2ry12 plays a critical role in microglia-neuron communication, particularly in neurodegenerative conditions. As a highly expressed receptor in homeostatic microglia, P2ry12 mediates the rapid chemotactic response of microglial processes toward sites of injury or neuronal activity . Current research is revealing several key aspects of this communication:

• Synaptic pruning: P2ry12-expressing microglia interact with neuronal synapses during development and in pathological conditions. This interaction facilitates synaptic pruning, which may be dysregulated in neurodegenerative diseases.

• Response to neuronal damage: ATP released from damaged neurons acts as a "find-me" signal that attracts microglial processes through P2ry12 signaling. This response is critical for the containment of damage and initiation of repair processes.

• Microglial morphological states: In pathologically-involved brains, P2ry12 expression identifies microglia with various morphologies associated with different activation states , suggesting a role in morphological transitions during neurodegeneration.

• Neuroinflammatory modulation: P2ry12 expression is typically downregulated in pro-inflammatory conditions, suggesting that changes in P2ry12 levels may shift the balance between protective and detrimental microglial functions in neurodegenerative diseases.

Emerging research using single-cell technologies and in vivo imaging is further elucidating the dynamic regulation of P2ry12 in microglia-neuron interactions and its potential as a therapeutic target in neurodegenerative conditions.

What are the latest findings regarding P2ry12 as a biomarker in neurological disorders?

Recent research is establishing P2ry12 as a valuable biomarker in neurological disorders with several important applications:

• Microglial identification: P2ry12 serves as a reliable marker for homeostatic microglia in the central nervous system. Its expression pattern helps distinguish resident microglia from infiltrating macrophages in neuroinflammatory conditions .

• Disease progression monitoring: Changes in microglial P2ry12 expression correlate with disease progression in various neurological disorders. Decreased expression typically indicates microglial activation and neuroinflammation.

• Therapeutic response assessment: P2ry12 expression levels can be used to monitor microglial responses to therapeutic interventions, particularly those targeting neuroinflammation.

• Diagnostic applications: P2ry12 immunostaining patterns in post-mortem brain tissue can help characterize microglial states in different neurological conditions, providing diagnostic and prognostic information .

• PET imaging development: Radioligands targeting P2ry12 are being developed for PET imaging, potentially allowing non-invasive monitoring of microglial activation in living patients.

The utility of P2ry12 as a biomarker extends beyond neurological disorders to conditions affecting other tissues where P2ry12 is expressed, such as vascular disorders involving platelets. This expanding application of P2ry12 as a biomarker highlights its importance in understanding disease mechanisms and developing targeted therapies.

How do post-translational modifications affect P2ry12 function and signaling?

Post-translational modifications (PTMs) significantly influence P2ry12 function and signaling, though this area remains incompletely characterized:

• Glycosylation: P2ry12 contains potential N-linked glycosylation sites that may affect receptor folding, stability, and ligand binding. Different glycosylation patterns between recombinant and native P2ry12 may explain functional differences observed in various experimental systems.

• Phosphorylation: Upon activation, P2ry12 is phosphorylated by G protein-coupled receptor kinases (GRKs), creating binding sites for arrestins . This phosphorylation is critical for arrestin recruitment and subsequent receptor internalization. The specific phosphorylation sites and their individual contributions to receptor regulation remain to be fully characterized.

• Ubiquitination: Following internalization, P2ry12 may undergo ubiquitination, which could influence its post-endocytic sorting between recycling and degradative pathways. The balance between receptor recycling and degradation is crucial for maintaining appropriate receptor levels at the cell surface.

• Palmitoylation: As a G protein-coupled receptor, P2ry12 may undergo palmitoylation, which can affect its localization in membrane microdomains and coupling to downstream signaling pathways.

• Proteolytic processing: Potential proteolytic cleavage of P2ry12 could generate receptor fragments with altered signaling properties or dominant-negative effects.

Understanding how these PTMs are regulated in different cell types and pathological conditions may reveal new opportunities for therapeutic intervention by selectively modulating specific aspects of P2ry12 function and signaling.